"Model T" cells: A time-tested vehicle for gene therapy

Frontiers in Immunology

Volumn 4, Issue SEP, 2013, Pages

  Kerkar, Sid P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chimeric antigen receptors; Cytokines; Gene therapy; Immunotherapy; Inflammation; Severe combined immunodeficiency; T cells

Indexed keywords

B CELL MATURATION ANTIGEN; B7 ANTIGEN; CD134 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GANGLIOSIDE GD2; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 7; INTERLEUKIN 8; PROSTATE STEM CELL ANTIGEN; RANTES; T LYMPHOCYTE RECEPTOR; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; CLINICAL TRIAL (TOPIC); DOWN REGULATION; GENE THERAPY; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; MEMORY T LYMPHOCYTE; MUTATION; PROTEIN EXPRESSION; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; TUMOR REGRESSION;

EID: 84885981028     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00304     Document Type: Review

References (76)

1. Friedmann T. A brief history of gene therapy. Nat Genet (1992) 2(2):93-8. doi: 10.1038/ng1092-93.
2. Varmus HE. Form and function of retroviral proviruses. Science (1982) 216(4548):812-20. doi:10.1126/science.6177038.
3. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 7(1):33-40. doi:10.1038/83324.
4. WolffJA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet (2005) 54:3-20.
5. Gao X, Kim KS, Liu D. Nonviral gene delivery: what we know and what is next. AAPS J (2007) 9(1):E92-104. doi:10.1208/aapsj0901009.
6. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet (2011) 12(5):301-15. doi:10.1038/nrg2985.
7. Hwu P, Rosenberg SA. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detect Prev (1994) 18(1):43-50.
8. Brenner MK. Gene transfer and the treatment of haematological malignancy. J Intern Med (2001) 249(4):345-58. doi:10.1046/j.1365-2796.2001.00807.x.
9. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 4(132):132ra153. doi:10.1126/scitranslmed.3003761.
10. Rao MS, Collins FS. Steering a new course for stem cell research: NIH's intramural center for regenerative medicine. Stem Cells Transl Med (2012) 1(1):15-7. doi:10.5966/sctm.2011-0032.
11. Varmus H, Kumar HS. Addressing the growing international challenge of cancer: a multinational perspective. Sci Transl Med (2013) 5(175):175cm172. doi:10.1126/scitranslmed.3005899.
12. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 13(8):525-41. doi:10.1038/nrc3565.
13. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 323(9):570-8. doi:10.1056/NEJM199008303230904.
14. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 12(4):269-81. doi:10.1038/nri3191.
15. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 1(6):447-56. doi:10.1016/1074-7613(94)90087-6.
16. Rosenzweig SD, Holland SM. Recent insights into the pathobiology of innate immune deficiencies. Curr Allergy Asthma Rep (2011) 11(5):369-77. doi:10.1007/s11882-011-0212-9.
17. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 368(2):161-70. doi:10.1056/NEJMra1202117.
18. Mellman I, Coukos G, DranoffG. Cancer immunotherapy comes of age. Nature (2011) 480(7378):480-9. doi:10.1038/nature10673.
19. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 11(11):805-12. doi:10.1038/nrc3153.
20. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 3(2):133-46. doi:10.1038/nri1001.
21. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 13(2):155-68. doi:10.1016/S1359-6101(01)00032-6.
22. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 121(12):4746-57. doi:10.1172/JCI58814.
23. Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther (2013) 21(7):1369-77. doi:10.1038/mt.2013.58.
24. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 70(17):6725-34. doi:10.1158/0008-5472.CAN-10-0735.
25. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res (2011) 71(17):5697-706. doi:10.1158/0008-5472.CAN-11-0103.
26. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther (2011) 19(4):751-9. doi:10.1038/mt.2010.313.
27. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res (2012) 18(6):1672-83. doi:10.1158/1078-0432.CCR-11-3050.
28. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 119(18):4133-41. doi:10.1182/blood-2011-12-400044.
29. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med (2011) 17(10):1290-7. doi:10.1038/nm.2446.
30. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood (2011) 117(3):808-14. doi:10.1182/blood-2010-05-286286.
31. KlebanoffCA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 17(16):5343-52. doi:10.1158/1078-0432.CCR-11-0503.
32. Muranski P, Borman ZA, Kerkar SP, KlebanoffCA, Ji Y, Sanchez-Perez L, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 35(6):972-85. doi:10.1016/j.immuni.2011.09.019.
33. Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther (2008) 19(5):496-510. doi:10.1089/hum.2007.0171.
34. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res (2010) 16(22):5458-68. doi:10.1158/1078-0432.CCR-10-0712.
35. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res (2012) 18(10):2780-90. doi:10.1158/1078-0432.CCR-11-1920.
36. Riddell SR, Jensen MC, June CH. Chimeric antigen receptor-modified T cells: clinical translation in stem cell transplantation and beyond. Biol Blood Marrow Transplant (2013) 19(1 Suppl):S2-5. doi:10.1016/j.bbmt.2012.10.021.
37. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3(4):388-98. doi:10.1158/2159-8290.CD-12-0548.
38. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 116(19):3875-86. doi:10.1182/blood-2010-01-265041.
39. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 3(95):95ra73. doi:10.1126/scitranslmed.3002842.
40. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 365(8):725-33. doi:10.1056/NEJMoa1103849.
41. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 5(177):177ra138. doi:10.1126/scitranslmed.3005930.
42. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 47(4):1098-104.
43. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 119(17):3940-50. doi:10.1182/blood-2011-10-387969.
44. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2013) 121(7):1165-74. doi:10.1182/blood-2012-06-438002.
45. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res (2013) 19(8):2048-60. doi:10.1158/1078-0432.CCR-12-2422.
46. Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, Takei Y, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia (2012) 26(2):365-7. doi:10.1038/leu.2011.205.
47. Giordano Attianese GM, Marin V, Hoyos V, Savoldo B, Pizzitola I, Tettamanti S, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood (2011) 117(18):4736-45. doi:10.1182/blood-2010-10-311845.
48. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 113(25):6392-402. doi:10.1182/blood-2009-03-209650.
49. Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol (2012) 2012:683065. doi:10.1155/2012/683065.
50. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 23(10):1043-53. doi:10.1089/hum.2012.041.
51. Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate (2007) 67(10):1121-31. doi:10.1002/pros.20608.
52. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate (2004) 61(1):12-25. doi:10.1002/pros.20073.
53. Merhavi-Shoham E, Haga-Friedman A, Cohen CJ. Genetically modulating T-cell function to target cancer. Semin Cancer Biol (2012) 22(1):14-22. doi:10.1016/j.semcancer.2011.12.006.
54. Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol (2013) 190(12):6034-42. doi:10.4049/jimmunol.1202830.
55. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 19(6):747-52. doi:10.1038/nm.3161.
56. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 29(7):917-24. doi:10.1200/JCO.2010.32.2537.
57. Shahinian A, Pfeffer K, Lee KP, Kündig TM, Kishihara K, Wakeham A, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science (1993) 261(5121):609-12. doi:10.1126/science.7688139.
58. Radvanyi LG, Shi Y, Vaziri H, Sharma A, Dhala R, Mills GB, et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol (1996) 156(5):1788-98.
59. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res (2006) 66(22):10995-1004. doi:10.1158/0008-5472.CAN-06-0160.
60. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med (2010) 2(55):55ra78. doi:10.1126/scitranslmed.3000448.
61. Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood (2012) 119(3):696-706. doi:10.1182/blood-2011-03-344275.
62. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science (1995) 270(5235):475-80. doi:10.1126/science.270.5235.475.
63. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood (2003) 101(7):2563-9. doi:10.1182/blood-2002-09-2800.
64. Cavazzana-Calvo M, Hacein-Bey S, de SaintBasile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 288(5466):669-72. doi:10.1126/science.288.5466.669.
65. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene (2013) 525(2):170-73. doi:10.1016/j.gene.2013.03.092.
66. Knight S, Collins M, Takeuchi Y. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis. Curr Gene Ther (2013) 13(3):211-27. doi:10.2174/1566523211313030006.
67. Romano G. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN Oncol (2012) 2012:616310. doi:10.5402/2012/616310.
68. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 365(18):1673-83. doi:10.1056/NEJMoa1106152.
69. Aksentijevich I, Kastner DL. Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol (2011) 7(8):469-78. doi:10.1038/nrrheum.2011.94.
70. Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol (2012) 12(8):570-80. doi:10.1038/nri3261.
71. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest (2007) 117(3):514-21. doi:10.1172/JCI30587.
72. Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, Ariga T, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis (2010) 45(3):246-65. doi:10.1016/j.bcmd.2010.07.012.
73. Roychoudhuri R, Hirahara K, Mousavi K, Clever D, KlebanoffCA, Bonelli M, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 498(7455):506-10. doi:10.1038/nature12199.
74. Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev Immunol (2013) 13(9):635-48. doi:10.1038/nri3493.
75. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 326(5954):818-23. doi:10.1126/science.1171242.
76. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 365(25):2357-65. doi:10.1056/NEJMoa1108046.